Logo image of ALBIO.PA

BIOSYNEX (ALBIO.PA) Stock Price, Forecast & Analysis

Europe - Euronext Paris - EPA:ALBIO - FR0011005933 - Common Stock

0.726 EUR
+0 (+0.55%)
Last: 1/19/2026, 7:00:00 PM

ALBIO.PA Key Statistics, Chart & Performance

Key Statistics
Market Cap13.61M
Revenue(TTM)97.95M
Net Income(TTM)-70.99M
Shares18.75M
Float7.71M
52 Week High1.98
52 Week Low0.46
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-4.31
PEN/A
Fwd PE1.53
Earnings (Next)N/A
IPO2011-03-21
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
ALBIO.PA short term performance overview.The bars show the price performance of ALBIO.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 -40

ALBIO.PA long term performance overview.The bars show the price performance of ALBIO.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ALBIO.PA is 0.726 EUR. In the past month the price increased by 19.02%. In the past year, price decreased by -51.21%.

BIOSYNEX / ALBIO Daily stock chart

ALBIO.PA Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to ALBIO.PA. When comparing the yearly performance of all stocks, ALBIO.PA is a bad performer in the overall market: 91.6% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ALBIO.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ALBIO.PA. ALBIO.PA may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALBIO.PA Financial Highlights

Over the last trailing twelve months ALBIO.PA reported a non-GAAP Earnings per Share(EPS) of -4.31. The EPS decreased by -41.1% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -47.5%
ROE -160.22%
Debt/Equity 0.31
Chartmill High Growth Momentum
EPS Q2Q%-56.71%
Sales Q2Q%-5.91%
EPS 1Y (TTM)-41.1%
Revenue 1Y (TTM)-5.84%

ALBIO.PA Forecast & Estimates

For the next year, analysts expect an EPS growth of 475% and a revenue growth 15.05% for ALBIO.PA


Analysts
Analysts86.67
Price TargetN/A
EPS Next Y475%
Revenue Next Year15.05%

ALBIO.PA Ownership

Ownership
Inst Owners0.39%
Ins Owners5.7%
Short Float %N/A
Short RatioN/A

ALBIO.PA Competitors/Peers

The largest stocks on the EU markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
2M6.DE MEDTRONIC PLC 17.25 107.02B
1SHL.MI SIEMENS HEALTHINEERS AG 19.62 52.88B
SHL.DE SIEMENS HEALTHINEERS AG 18.56 50.05B
1PHIA.MI KONINKLIJKE PHILIPS NV 17.36 24.74B
PHIA.AS KONINKLIJKE PHILIPS NV 16.39 23.35B
PHI1.DE KONINKLIJKE PHILIPS NV 16.51 23.53B
BIM.PA BIOMERIEUX 26.66 12.18B
OBCK.DE OTTOBOCK SE & CO KGAA 138.3 4.16B
DIA.MI DIASORIN SPA 22.23 4.12B
1AFX.MI CARL ZEISS MEDITEC AG - BR 23.24 3.55B
AFX.DE CARL ZEISS MEDITEC AG - BR 21.8 3.14B
DRW3.DE DRAEGERWERK AG - PREF 13.61 1.65B

Related stock screener links

About ALBIO.PA

Company Profile

ALBIO logo image Biosynex SA engages in the provision of development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 486 full-time employees. The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.

Company Info

BIOSYNEX

22 Boulevard Sebastien Brant

Illkirch-Graffenstaden GRAND EST FR

Employees: 515

ALBIO Company Website

ALBIO Investor Relations

Phone: 33388787887

BIOSYNEX / ALBIO.PA FAQ

What does ALBIO do?

Biosynex SA engages in the provision of development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 486 full-time employees. The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.


Can you provide the latest stock price for BIOSYNEX?

The current stock price of ALBIO.PA is 0.726 EUR. The price increased by 0.55% in the last trading session.


What is the dividend status of BIOSYNEX?

ALBIO.PA does not pay a dividend.


What is the ChartMill technical and fundamental rating of ALBIO stock?

ALBIO.PA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


How is the valuation of BIOSYNEX (ALBIO.PA) based on its PE ratio?

BIOSYNEX (ALBIO.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.31).


What is the ownership structure of BIOSYNEX (ALBIO.PA)?

You can find the ownership structure of BIOSYNEX (ALBIO.PA) on the Ownership tab.